Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HPGD | P15428 | 1/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.43 |
| ▸ | PDE4A | P27815 | 11/20 | 0.42 |
| ▸ | PDE4B | Q07343 | 6/20 | 0.42 |
| ▸ | PDE4C | Q08493 | 6/20 | 0.42 |
| ▸ | PDE4D | Q08499 | 6/20 | 0.42 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
| ▸ | TP53 | P04637 | 1/20 | 0.38 |
| ▸ | POLB | P06746 | 1/20 | 0.37 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4462149 | 0.89 | SMN1; SMN2 (0.48) | HPGDSMN1; SMN2PDE4APDE4BPDE4C | |
| SCHEMBL4457353 | 0.89 | SMN1; SMN2 (0.48) | HPGDSMN1; SMN2PDE4APDE4BPDE4C | |
| SCHEMBL4476149 | 0.87 | HPGD (0.46) | HPGDSMN1; SMN2PDE4APDE4BPDE4C | |
| SCHEMBL4471223 | 0.85 | PDE4A (0.42) | HPGDSMN1; SMN2PDE4APDE4BPDE4C | |
| SCHEMBL4458772 | 0.82 | SMN1; SMN2 (0.47) | HPGDSMN1; SMN2PDE4APDE4BPDE4C | |
| SCHEMBL4458893 | 0.82 | SMN1; SMN2 (0.43) | HPGDSMN1; SMN2PDE4APDE4BPDE4C | |
| SCHEMBL4465195 | 0.82 | SMN1; SMN2 (0.47) | HPGDSMN1; SMN2PDE4APDE4BPDE4C | |
| SCHEMBL4458799 | 0.82 | SMN1; SMN2 (0.47) | HPGDSMN1; SMN2PDE4APDE4BPDE4C | |
| SCHEMBL4475761 | 0.81 | HPGD (0.45) | HPGDSMN1; SMN2PDE4APDE4BPDE4C | |
| SCHEMBL4455116 | 0.81 | SMN1; SMN2 (0.45) | HPGDSMN1; SMN2PDE4APDE4BPDE4C |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7585882-B2 | Phosphodiesterase 4 inhibitors | MEMORY PHARMACEUTICALS CORPORATION (US) | 2009-09-08 | — | — | US | claimed |
| EP-1802615-A1 | PHOSPHODIESTERASE 4 INHIBITORS | Memory Pharmaceuticals Corporation (US) | 2007-07-04 | — | — | EP | claimed |
| US-20060135535-A1 | 4-(substituted-phenyl)-2-pyrrolidinones; reduced emetic side effects; antiinflammatory agents; neurological syndromes, asthma, arthritis | MEMORY PHARMACEUTICALS CORPORATION | 2006-06-22 | — | — | US | claimed |
| WO-2006044955-A1 | PHOSPHODIESTERASE 4 INHIBITORS | MEMORY PHARMACEUTICALS CORPORATION (US) | 2006-04-27 | — | — | WO | claimed |
| US-20090306156-A1 | PHOSPHODIESTERASE 4 INHIBITORS | HOPPER ALLEN | 2009-12-10 | — | — | US | disclosed |
| US-20090306156-A1 | PHOSPHODIESTERASE 4 INHIBITORS | HOPPER ALLEN | 2009-12-10 | — | — | US | disclosed |
| US-20090306156-A1 | PHOSPHODIESTERASE 4 INHIBITORS | HOPPER ALLEN | 2009-12-10 | — | — | US | disclosed |
| US-7585882-B2 | Phosphodiesterase 4 inhibitors | MEMORY PHARMACEUTICALS CORPORATION (US) | 2009-09-08 | — | — | US | disclosed |
| US-7585882-B2 | Phosphodiesterase 4 inhibitors | MEMORY PHARMACEUTICALS CORPORATION (US) | 2009-09-08 | — | — | US | disclosed |
| US-7585882-B2 | Phosphodiesterase 4 inhibitors | MEMORY PHARMACEUTICALS CORPORATION (US) | 2009-09-08 | — | — | US | disclosed |
| WO-2009067607-A2 | COMBINATIONS OF PDE4 INHIBITORS AND ANTIPSYCHOTICS FOR THE TREATMENT OF PSYCHOTIC DISORDERS | MEMORY PHARMACEUTICALS CORPORATION (US) | 2009-05-28 | — | — | WO | disclosed |
| EP-1802615-A1 | PHOSPHODIESTERASE 4 INHIBITORS | Memory Pharmaceuticals Corporation (US) | 2007-07-04 | — | — | EP | disclosed |
| US-20060135535-A1 | 4-(substituted-phenyl)-2-pyrrolidinones; reduced emetic side effects; antiinflammatory agents; neurological syndromes, asthma, arthritis | MEMORY PHARMACEUTICALS CORPORATION | 2006-06-22 | — | — | US | disclosed |
| WO-2006044955-A1 | PHOSPHODIESTERASE 4 INHIBITORS | MEMORY PHARMACEUTICALS CORPORATION (US) | 2006-04-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060135535-A1 | 4-(substituted-phenyl)-2-pyrrolidinones; reduced emetic side effects; antiinflammatory agents; neurological syndromes, asthma, arthritis | PDE4A, PDE4B, PDE12 | HPGD 384/4885SMN1; SMN2 754/4885PDE4A 1/4885 |
| US-20090306156-A1 | PHOSPHODIESTERASE 4 INHIBITORS | PDE4A, PDE3B, PDE5A | HPGD 244/4885SMN1; SMN2 2959/4885PDE4A 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.